Longeveron Inc. announced that the World Health Organization (WHO) has approved the International Non-proprietary Name (INN) “laromestrocel” for their cellular therapy Lomecel-B™.
Lomecel-B™ is being evaluated as a treatment for Alzheimer’s disease and hypoplastic left heart syndrome (HLHS).
It is a proprietary product made from medicinal signaling cells and has received FDA designations such as Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designation for its potential.
The approval of the INN is an important step in the development and potential commercialization of Lomecel-B™.
Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines for unmet medical needs.
Listen to our latest podcast episode for more details: